ReShape Lifesciences Share Price OTC Markets

Equities

RSLS

US7611236032

Advanced Medical Equipment & Technology

End-of-day quote OTC Markets 23:00:00 07/07/2021 BST 5-day change 1st Jan Change
5.09 USD +23.84% Intraday chart for ReShape Lifesciences -.--% -.--%
Sales 2024 * 9.99M 787M Sales 2025 * 11.99M 944M Capitalization 4.13M 325M
Net income 2024 * -6M -472M Net income 2025 * -5M -394M EV / Sales 2024 * 0.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.34 x
P/E ratio 2024 *
-0.39 x
P/E ratio 2025 *
-0.49 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.83%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 31/01/20
Director of Finance/CFO 63 14/06/21
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 31/12/15
Chairman 70 31/10/15
Director/Board Member 70 14/06/21
More insiders
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1762 USD
Average target price
1 USD
Spread / Average Target
+467.54%
Consensus